Glamorous AI develops an artificial intelligence-driven platform for small molecule drug discovery, utilizing machine learning models and DNA-encoded library technology to enhance data analysis. This approach accelerates the identification of drug candidates, addressing the inefficiencies in traditional drug discovery processes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional small molecule drug discovery is often slow and inefficient, requiring extensive time and resources to identify viable drug candidates. Analyzing the vast amounts of data generated during drug discovery presents a significant bottleneck, hindering the rapid development of new medicines.
Solution
X-Chem provides an AI-driven platform, ArtemisAI, that accelerates small molecule drug discovery by enhancing data analysis and hit identification. Combining DNA-encoded library (DEL) technology with machine learning models, the platform streamlines the process of identifying and optimizing drug candidates. By leveraging extensive DEL data, ArtemisAI enables researchers to unlock the full potential of their datasets and expedite the hit-to-lead process. The platform's suite of machine learning models revolutionizes the discovery of new medicines, allowing for more efficient and effective drug development.
Target Audience
The primary customers are pharmaceutical companies and research institutions involved in small molecule drug discovery.
Features
- ArtemisAI: A proprietary AI platform utilizing machine learning models for enhanced data analysis
- DNA-encoded library (DEL) technology for efficient hit identification
- Hit-to-lead acceleration capabilities
- Proven track record with an 80% success rate in identifying functional hits
- Expertise in challenging target classes